Superior Planning, LLC’s Dianthus Therapeutics DNTH Stock Holding History

Superior Planning, LLC’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$21.7K	Buy	+247	New	+$25.6K	0.01%	664

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Superior Planning, LLC's DNTH Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Dianthus Therapeutics (DNTH) in Q3 2026: 247 shares worth $21.7K. The stake represents 0.01% of the portfolio and ranks #664 among its holdings.

141 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

Superior Planning, LLC held 247 shares of Dianthus Therapeutics worth $21.7K as of Q3 2026.
Dianthus Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Dianthus Therapeutics made up 0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #664 holding.
141 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.